NEWTOWN, Pa., March 2, 2017 /PRNewswire/ -- Micro Interventional Devices, Inc™ (MID), is pleased to announce that
"Receiving the 2017 'Top Cardiovascular Innovation Award' at one of the world's leading interventional cardiology conferences is an honor," said Michael Whitman. "The promising early data from our STTAR Study in the EU indicates that our MIA technology is effective in reducing annular dimensions and tricuspid regurgitation. CRT's recognition of the encouraging clinical results and the potential for MIA to provide an effective percutaneous solution for the treatment of tricuspid and mitral valve disease is a tremendous accomplishment for our team."
The MIA technology is designed to reduce annular dimensions and regurgitation during percutaneous transcatheter mitral and tricuspid repair. The annular reduction is achieved without sutures or other intervention due to the compliant, self-tensioning MIA implant incorporating the company's proprietary PolyCor™ anchors and MyoLast™ implantable elastomer.
About Micro Interventional Devices, Inc. (MID):
MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.
Company Contact: Micro Interventional Devices, Inc. Katherine Whitman Product Director 215 600 1270 [email protected] www.microinterventional.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/micro-interventional-devices-inc-wins-crt-2017s-top-cardiovascular-innovation-award-for-mia-minimally-invasive-annuloplasty-technology-300417050.html
SOURCE Micro Interventional Devices, Inc.
Subscribe to our Free Newsletters!
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...View All